Table 1 Patient Characteristics
All (n = 204) | With Anti-Angiogenesis (n = 60) | Without Anti-Angiogenesis (n = 144) | p-value | ||
|---|---|---|---|---|---|
First line (n = 21) | Further line (n = 39) | ||||
Age ≥ 65 years | 75 (36.8) | 7 (33.3) | 7 (17.9) | 61 (42.4) | 0.018 |
Male | 68 (33.3) | 8 (38.1) | 14 (35.9) | 46 (31.9) | 0.796 |
Smoking | 41 (20.1) | 4 (19.0) | 8 (20.5) | 29 (20.1) | 0.990 |
ECOG PS ≥ 2 | 16 (7.8) | 1 (4.8) | 2 (5.1) | 13 (9.0) | 0.621 |
EGFR mutation | 0.086 | ||||
Del 19 | 107 (52.5) | 8 (38.1) | 24 (61.5) | 75 (52.1) | |
L858R | 88 (43.1) | 10 (47.6) | 15 (38.5) | 63 (43.7) | |
Uncommon | 9 (4.4) | 3 (14.3) | 0 (0) | 6 (4.2) | |
Metastasis Organ | |||||
Lung metastasis | 102 (50.0) | 10 (47.6) | 20 (51.3) | 72 (50.0) | 0.964 |
LN metastasis | 141 (69.1) | 13 (61.9) | 26 (66.7) | 102 (70.8) | 0.663 |
Pleural metastasis | 92 (45.1) | 5 (23.8) | 16 (41.0) | 71 (49.3) | 0.076 |
Liver metastasis | 40 (19.6) | 5 (23.8) | 9 (23.1) | 26 (18.1) | 0.686 |
Bone Metastasis | 106 (52) | 14 (66.7) | 22 (56.4) | 70 (48.6) | 0.249 |
CNS metastasis | 47 (23) | 3 (14.3) | 8 (20.5) | 36 (25.0) | 0.506 |
Adrenal metastasis | 26 (12.7) | 3 (14.3) | 3 (7.7) | 20 (13.9) | 0.574 |
EGFR-TKI | 0.041 | ||||
Gefitinib | 51 (25.0) | 3 (5.3) | 7 (18.4) | 41 (10.8) | |
Erlotinib | 77 (37.7) | 11 (52.4) | 10 (25.6) | 56 (38.9) | |
Afatinib | 76 (37.3) | 7 (33.3) | 22 (56.4) | 47 (32.6) | |
Anti-VEGF | < 0.001 | ||||
Bevacizumab | 39 (19.1) | 17 (81.0) | 22 (56.4) | 0 (0) | |
Ramucizumab | 21 (10.3) | 4 (19.0) | 17 (43.6) | 0 (0) | |